Financials data is unavailable for this security.
View more
Year on year Towa Pharmaceutical Co Ltd grew revenues 9.13% from 208.86bn to 227.93bn. In addition the company has reduced the cost of goods sold as a percent of sales, selling, general and administrative expenses as a percent of sales and interest paid as a percent of sales. These improvements contributed to 634.80% net income growth from 2.20bn to 16.17bn.
| Gross margin | 35.90% |
|---|---|
| Net profit margin | 7.17% |
| Operating margin | 10.19% |
| Return on assets | 4.00% |
|---|---|
| Return on equity | 11.02% |
| Return on investment | 4.91% |
More ▼
Cash flow in JPYView more
In 2024, Towa Pharmaceutical Co Ltd increased its cash reserves by 22.23%, or 5.39bn. Cash Flow from Financing totalled 35.41bn or 15.53% of revenues. In addition the company generated 8.21bn in cash from operations while cash used for investing totalled 40.39bn.
| Cash flow per share | 716.74 |
|---|---|
| Price/Cash flow per share | 4.59 |
| Book value per share | 3,311.49 |
|---|---|
| Tangible book value per share | 2,297.49 |
More ▼
Balance sheet in JPYView more
| Current ratio | 2.94 |
|---|---|
| Quick ratio | 1.62 |
| Total debt/total equity | 1.31 |
|---|---|
| Total debt/total capital | 0.5666 |
More ▼
Growth rates in JPY
Year on year, growth in dividends per share remained flat while earnings per share excluding extraordinary items increased 634.82%. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked in-line with the industry average relative to its peers.
| Div yield(5 year avg) | 2.16% |
|---|---|
| Div growth rate (5 year) | 10.86% |
| Payout ratio (TTM) | 17.45% |
| EPS growth(5 years) | 5.34 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 204.51 |
More ▼
